Recent Investment Analysts’ Ratings Changes for Sagimet Biosciences (SGMT)

Sagimet Biosciences (NASDAQ: SGMT) has recently received a number of price target changes and ratings updates:

• 9/9/2026 – Sagimet Biosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $10.71 price target on the stock.
• 9/9/2026 – Sagimet Biosciences was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $18.00 price target on the stock, up from $8.00.
• 9/9/2026 – Sagimet Biosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $10.71 price target on the stock.
• 8/25/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
• 8/15/2026 – Sagimet Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/14/2026 – Sagimet Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/14/2026 – Sagimet Biosciences had its price target raised by Citizens Jmp from $12.00 to $29.00. They now have a “market outperform” rating on the stock.
• 8/12/2026 – Sagimet Biosciences had its price target raised by Canaccord Genuity Group Inc. from $49.00 to $56.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Sagimet Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Sagimet Biosciences

In other Sagimet Biosciences news, CEO David Happel sold 64,051 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total transaction of $497,035.76. Following the transaction, the chief executive officer directly owned 741,570 shares in the company, valued at $5,754,583.20. This represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the sale, the director owned 62,161 shares in the company, valued at approximately $618,501.95. The trade was a 24.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 113,646 shares of company stock valued at $920,491 over the last 90 days. 11.50% of the stock is currently owned by corporate insiders.

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company developing therapies for diseases associated with abnormal lipid metabolism. The company’s primary focus is fatty acid synthase (FASN), an enzyme involved in the production of fatty acids that can contribute to disease progression in certain metabolic and inflammatory conditions.

Sagimet’s lead product candidate is denifanstat, formerly known as TVB-2640. Denifanstat is an orally administered, selective FASN inhibitor being evaluated primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can lead to fibrosis, cirrhosis and other serious complications.